Sandoz, a global leader in generic and biosimilar medicines, announced the launch of a new global initiative called ‘Act4Biosimilars’ to help address health inequity and inequality worldwide. Act4Biosimilars aims to increase patient access to advanced medicines by facilitating greater approvability, accessibility, acceptability and affordability (the 4 A’s) of biosimilars.
Sandoz announces new global ‘Act4Biosimilars’ initiative
June 3, 2022
![Sandoz announces new global ‘Act4Biosimilars’ initiative](https://www.worldpharmanews.com/images/logo/novartis.png)